Kornimate/medical-research-clean huggingface dataset:
oncoliq: test for early breast cancer detection.

Conditions: Breast Cancer

Summary: oncoliq is a novel early breast cancer detection test based on liquid biopsies and micrornas. this innovative test will allow improving the accuracy of cancer detection which will impact on health, reducing the patient mortality and health costs. to develop this test, it has been finished the preclinical phase i: in laboratory animals; phase ii: exploratory clinical phase for the discovery of candidate biomarkers in breast cancer patients and phase iii: clinical validation of biomarkers showing that oncoliq has 91% of sensitivity. currently it is been setting up a "pilot test" for breast cancer to enrol 500 woman volunteers without previous cancer diagnosis that go to the annual medical control. the results of the pilot test will give the accuracy for early breast cancer detection.


Eligibility criteria:
inclusion criteria: * women patients performing gynecological control * between 50-70 years old * without personal history of oncological disease * informed consent signed exclusion criteria: * patients who don´t meet the inclusion criteria. * active infection with sars-cov-2 (covid-19).

Keywords: liquid biopsy, breast cancer, early detection, micrornas.
pediatric expanded access program-oral solution (0831-908)

Conditions: HIV Infections

Summary: monitor the safety and tolerability of efavirenz oral solution in combination with antiretroviral therapy for the treatment of patients age 3 to 16 years who have failed therapy or who are intolerant to their current therapy. this is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (full information is available to trial participants).


Eligibility criteria:
inclusion criteria: * not tolerating current art regime laboratory status is stable * able to take oral liquid medications but have difficulty swallowing capsules * weigh at least 10 kg (22 lbs) exclusion criteria: * has had more than 2 episodes of moderate to severe diarrhea or vomiting lasting more than 4 days within 3 months prior to taking study drug * have taken another investigational drug 30 days before starting this study * have a history of drug or alcohol abuse

Keywords: hiv treatment experienced
a lifecourse map of diseases in china

Conditions: Common Diseases; Rare Diseases

Summary: the purpose of this study is to form a chronological map of common diseases and rare diseases in chinese population by determining the prevalence of different diseases in each age group.

studying the distribution of various diseases in specific populations can help explore the causes of diseases, elucidate the distribution patterns, and develop preventive and control measures. based on an overall assessment of prevalence, the combination of relevant results with age at diagnosis for multiple diseases is important for further understanding of the distribution of diseases at the population level. therefore, this study aims to form a chronological map of common diseases and rare diseases in chinese population by determining the prevalence of different diseases in each age group, thus providing a reference for more effective prevention, diagnosis and treatment of diseases.

Eligibility criteria:
inclusion criteria: 1. all inpatients within the period of january 1, 2017 to december 31, 2021. 2. patients with discharge diagnosis. 3. patients with accurate gender and age records. exclusion criteria: 1. morbidity and mortality due to external causes, i.e. injuries, poisonings and other adverse events due to external environment and accidents. 2. pregnancy-related conditions. 3. symptoms, signs, abnormal clinical and laboratory findings. 4. traditional chinese medicine diagnosis records. 5. patients with incorrect or missing disease codes.
pilot trial: the safety and feasibility of losartan for pulmonary vein stenosis

Conditions: Pulmonary Vein Stenosis; Children

Summary: this pilot study evaluates the safety and feasibility of losartan in pediatric patients with pulmonary vein stenosis. it is an open label single arm interventional study. the patient population involves pediatric patients with stenosis in 2 or more pulmonary veins. patients will be given losartan for 1 year. outcomes include measures of safety/adverse events and progression of pulmonary vein stenosis.

this pilot study evaluates the safety and feasibility of losartan in pediatric patients with pulmonary vein stenosis. large animal studies have demonstrated that losartan can ameliorate the progression of pulmonary vein stenosis in a surgical model of pulmonary vein stenosis. there is no safety data for losartan in children \< 6months of age or in children with pulmonary vein stenosis. therefore, this study will test the safety and feasibility of losartan in children in an open label single arm interventional study. patient inclusion criteria includes stenosis involving 2 or more pulmonary veins. patients who are consented into the trial with be on losartan therapy for one year. they will undergo study visits every 3 months. patients will be screened for adverse events through biochemical tests, routine clinical tests and questionnaires. an exploratory efficacy analysis will compare progression of pulmonary vein stenosis in children enrolled in losartan to a contemporary cohort of children with pulmonary vein stenosis, who did not receive losartan.

Eligibility criteria:
inclusion criteria: * stenosis involving 2 or more pulmonary veins * consent of parent/legal guardian or child(when appropriate) exclusion criteria: * history of angioedema or allergic reaction to angiotensin converting enzyme inhibitors * corrected gestational age of less than 40 weeks * severe renal dysfunction * pregnancy
australian genomics of chronic allograft dysfunction study

Conditions: Kidney Transplant Rejection; Kidney Transplant; Complications

Summary: the goal of the australian genomics of chronic allograft dysfunction (auscad) study is a single centre (westmead hospital), prospective, observational study, which enrols patients at time of kidney (or kidney-transplant) transplant and tracks the post transplant course. the auscad study aims to generate new knowledge and improve outcomes following kidney transplantation. the primary aim is to determine whether important outcomes (including chronic rejection and graft loss) are correlated with patterns of allograft reactivity, gene expression and susceptibility profiles.


Eligibility criteria:
inclusion criteria: * living or deceased donor kidney transplant candidate. * biological sex: any * ages: 18-75 years. * subject must be able to understand and provide informed consent. * deceased donor individuals where research consent has been obtained from the person consenting to organ donation at the time of organ retrieval. * identifiable living donors who have received informed consent and have consented to participate in the project. exclusion criteria: * presensitization in living donor recipients prior to transplantation, as determined by site-specific standards, or positive cross match according to site specific technique in cadaveric donor recipients. * recipients of multiple organ transplants, with the exception of kidney/pancreas transplants. * inability or unwillingness of a participant to give written informed consent or comply with study protocol * high risk populations including pregnant women, children less than 18 years and prisoners will not be included in the study. * non english speaking potential participants who do not understand the requirements of the study will not be included.
corneal endothelium after phacoemulsification in pseudo exfoliation syndrome

Conditions: Corneal Endothelial Cell Loss; Pseudoexfoliation Syndrome

Summary: to study corneal endothelial cells changes after phacoemulsification in patients with senile cataract and pseudoexfoliation syndrome (pex) compared with control patients with senile cataract using specular microscope.

in a prospective interventional case-control study, 20 eyes with cataract and pex and 20 control eyes with cataract without pxe were subjected to phacoemulsification and posterior chamber foldable intraocular lens implantation in minia university hospital and genaidy eye center between march 2019 and december 2020. specular microscopy was done preoperatively, 3 and 6 months postoperatively. endothelium cell density (ecd), coefficient variation (cv), hexagonality, pleomorphism and corneal thickness were evaluated and compares between pxe and control eyes.

Eligibility criteria:
inclusion criteria: * senile cataract age more than 55 years exclusion criteria: * pex with glaucoma, eyes with cornea guttata or any corneal dystrophy, zonular dehiscence, very dense nuclear cataract (cataracta nigra) history of previous ocular surgery.

Keywords: corneal endothelial cell loss, pseudoexfoliation syndrome , cataract
study of diagnostic biomarkers of acute acoustic trauma

Conditions: Acoustic Trauma

Summary: every year, more than two thousand acute acoustic trauma occur in france, equally between the military and the civilian environment. currently, acute acoustic trauma is a pathology with no specific validated treatment, and it is the cause of many handicapping situations. improving the future of patients requires a better understanding of the neurophysiological mechanisms of noise-induced hearing impairment. they are multiple and pure tone audiometry, the only reference examination, does not allow to differentiate them. moreover, in the aftermath of acute acoustic trauma, pure tone audiometry tends to improve spontaneously, but this recovery is misleading, as a number of studies in animals have shown that irreversible lesions remain. the hypothesis of this study is that it is possible to identify new entities, specific to the type of cochlear lesions, in order to clarify the diagnosis of acute acoustic trauma. these entities will be identified by the evaluation of noise-induced hearing impairment via a combination of molecular (proteomic and genomic), physiological and behavioral data. these diagnostic details may then be used to improve prevention or therapy.


Eligibility criteria:
inclusion criteria: * age between 18 and 40 * healthy individuals: without hearing pathology * patients: acute acoustic trauma diagnosis within 72h exclusion criteria: * history of hearing pathology * history of severe head injury * ototoxic drug therapy * abnormal otoscopy and/or tympanometry
ntla-2002 in adults with hereditary angioedema (hae)

Conditions: Hereditary Angioedema

Summary: this study will be conducted to evaluate the safety, tolerability, activity, pharmacokinetics, and pharmacodynamics of ntla-2002 in adults with hereditary angioedema (hae).


Eligibility criteria:
inclusion criteria: 1. age \>18 years 2. diagnosis of hae types i or ii 3. ability to provide evidence of hae attacks to meet the screening requirement 4. subjects must have access to, and the ability to use, ≥ 1 acute medication(s) to treat angioedema attacks. 5. adequate chemistry and hematology measures at screening 6. subjects must agree not to participate in another interventional study for the duration of this trial. 7. subjects must be capable of providing signed informed consent exclusion criteria: 1. concurrent diagnosis of any other type of recurrent angioedema 2. subjects who have known negative reaction or hypersensitivity to any lipid nanoparticles (lnp) component. 3. any condition that, in the investigator's opinion, could adversely affect the safety of the subject. 4. unwilling to comply with study procedures.
propositive (protecting positive people from meningococcal infection) follow-up study

Conditions: HIV/AIDS; Meningococcal Disease

Summary: the need for and timing of booster doses of meningococcal vaccines in people living with hiv (plwhiv) is currently unknown. as such it is impossible for clinicians to recommend booster doses or to know if and when these might be necessary.we propose to follow up a group of participants from the propositive study who received two doses of both menb (bexsero) and menacwy (menveo). this was a group of plwhiv between the ages 18-45 years. we propose following up these participants at 18 and 30 months post completion of two doses of vaccine and investigating their immunological response.


Eligibility criteria:
inclusion criteria: * received vaccination with bexsero and menveo during propositive study * able to sign fully informed consent * able to comply with study requirements exclusion criteria: • unwilling or unable to comply with study requirements
clinical trial to compare effectiveness of diuretics in hemodialysis patients with residual renal function

Conditions: Chronic Kidney Insufficiency; Hemodialysis Treatment; Diuresis Preserved

Summary: introduction: chronic kidney disease is characterized by a progressive deterioration of renal function. at the end of the progression, when complications occur (overhydration, electrolyte imbalances or retention of uremic toxins), a percentage of patients requiring renal replacement therapy (haemodialysis). when starting the haemodialysis, the patient holds the residual renal function (rrf) which is lost over time. to preserve the rrf, the patient is treated with diuretics loops and / or thiazide diuretics. the effect of this treatment is lost when renal function worsens. in this context, there are few studies that explore the use and effectiveness of diuretics in patients on haemodialysis 2. objectives and hypothesis: hypothesis: the treatment with furosemide and hydrochlorothiazide in haemodialysis patients with rrf could: * to decrease in weight gain between haemodialysis sessions. * to increase urine volume. * to decrease the ultrafiltration in haemodialysis sessions ( the long interdialytic interval) main objective:to asses the effect of combined hydrochlorothiazide-furosemide therapy on gain weight between haemodialysis sessions in patients with rrf secondary objective: to asses the effect of combined hydrochlorothiazide-furosemide therapy on dialytic, clinical and analytical variables and use of the antihypertensive treatment 3. methodology: randomized open clinical trial to compare the effectiveness of the administration of diuretics in haemodialysis patients with residual renal function in single centre. the population of study are patients with chronic renal disease in haemodialysis therapy that they preserve residual renal function ( more 200ml daily of urine). it will be a simple randomization, to asses the effect of combined hydrochlorothiazide-furosemide therapy after a of 15 days washout without diuretic treatment, patients will be randomized to receive or not receive combined diuretic treatment for 1 month. after a 1 month washout , the patients will be receive or not the treatment according to cross over trial.


Eligibility criteria:
inclusion criteria: * over 18 years * chronic kidney disease, stage 5 chronic kidney disease, in haemodialysis * renal residual function preserved(more or equal 200 ml daily of urine) * minimum 3 months on haemodialysis and wish to participate in this study exclusion criteria: * less 4 millequivalent of potassium plasma in interdialytic sessions or to require potassium intradialytic treatment. * less 1 kg of gain weight in the long interdialytic interval. * adverse effects with treatment in the past. * to refusal to participate in the study. * pregnancy or lactation period. * contraindication the use of diuretic therapy, according to pharmacological profile.

Keywords: residual renal function combined thiazide-furosemide therapy haemodialysis
pre-operative mri of esophagus cancer

Conditions: Esophagus Cancer; Diagnoses Disease

Summary: the role of mri in the management of esophageal cancer remains unclear and poorly studied. recent technical advances suggest that mri may become a powerful technique for the initial assessment of esophageal cancer, but also for the evaluation of response to neo-adjuvant treatment before surgery. this imaging study will be performed prospectively and consecutively in 60 patients included over a 18-month period in patients wîth newly diagnosed esophageal cancer. the aim of this study is to assess the accuracy of mri to visualize esophageal tumors, to assess tumor burden and potential contact with adjacent structures as well as associated lymph nodes. if chemotherapy or radio-chemotherapy treatment is indicated before surgery, we will also evaluate whether mri helps us to better evaluate the response to this treatment in comparison to pet-scan or echo. endoscopy which are the examinations currently performed to evaluate the effectiveness of these treatments. the images of the mri exams will be interpreted by 1 expert radiologist with no knowledge of the other imaging modalities and transmitted to the doctors in charge for possible consideration for the treatment. patients will then be followed for one year according to clinical management standards to study the data on treatment complications and cancer progression at one year. the main risk is the administration of a gadolinium chelate-based mri contrast product used routinely. there is also a risk that the results of the mri may influence the treatment initially planned for example by canceling a surgical procedure.

the study will be proppsed consecutively to all patients with a histologically proven diagnosis of esophageal cancer. an mri examination including morphological sequences (without and with injection of a gadolinium chelate) functional and dynamic will be carried out in all the patients for initial staging in addition to other diagnostic procedure performed in clinical routine in this indication that are the endo-ultrasonography, ct and pet scanner. in patients for whom neo-adjuvant treatment with chemotherapy or radio-chemotherapy will be decided and started, a second mri will be performed 4 to 6 weeks after the end of the neo-adjuvant treatment. the images of the mr exams will be interpreted by 1 expert radiologist blinded from data of other imaging modalities and transmitted to the doctors in charge of the patient for possible consideration for the treatment. patients will then be followed for one year according to regular recommandation to assess mortality / morbidity and pfs at 1 year.

Eligibility criteria:
inclusion criteria: * any pathologically proven oesophagus cancer exclusion criteria: * mri contraindication * pregnant women * cervical esophagus cancer

Keywords: mri oesophagus cancer staging
evaluating the use of a device called impulse oscillometry in participants with vocal cord disorders or asthma

Conditions: Breathing, Mouth; Lung Function Decreased; Vocal Cord Dysfunction; Laryngeal Obstruction; Asthma

Summary: this study will determine if airway resistance to airflow and pressure, measured by impulse oscillometry, is impacted in subjects with vocal cord disorders and whether these measurements are different when compared to subjects with asthma.


Eligibility criteria:
inclusion criteria: * vaccinated against covid-19 or testing negative for covid-19 by viral pct within 5 days before testing * willingness to perform breathing test * must be able to speak and understand english * documented diagnosis of asthma, documented clinical diagnosis of vocal cord dysfunction, or undergoing evaluation for vocal cord dysfunction exclusion criteria: * unable to provide consent or perform oscillometry test
cleveland kids run

Conditions: Childhood Obesity

Summary: a 12 month long program focused on making good food choices and exercise directed at 8-12 year olds and their caregivers. the program will consist of monthly educational meetings each teaching a new nutritional and exercise concept. children will be given weekly exercise schedules and their adherence to the program will be assessed. the study will culminate with an annual children's race in may.


Eligibility criteria:
inclusion criteria: * participants must be aged 8-12 years old and enrolled in kindergarten through 6th grade in a cleveland public school * participants must have at least a b-average or equivalent in the prior academic year * participants must have at least one part or guardian who is able to accompany the participant during exercise and educational sessions * participants must be willing to participate in the rite aid cleveland marathon ringling bros. and barnum \& bailey red nose run® at the end of the study exclusion criteria: * children who are younger than 8 years or older than 12 years * children whose parents who are unable or unwilling to provide informed consent, * children whose parents are are illiterate or non-english speaking or reading * children whose parents are unable or unwilling to accompany them to educational and exercise sessions * children with a medical condition that prevents them from unmonitored exercise * children who have not maintained an equivalent of a b-average in the prior academic year
partial breast proton therapy for early stage breast cancer

Conditions: Breast Cancer

Summary: the purpose of this is to determine the efficacy and toxicity of proton therapy when used to deliver partial breast radiotherapy in patients with early stage breast cancer with low or intermediate risk factors.

radiation therapy delivered to the whole breast is standard treatment following tumor removal for patients with early stage breast cancer. in selected patients, delivering the radiation treatment to only the part of the breast involved by the tumor may be a viable alternative. this can decrease the amount of normal tissues exposed to irradiation, potentially decrease side-effects and shorten the treatment time. proton beam can decrease the volume of normal tissues treated compared to standard forms of radiotherapy. this study will recruit patients with early stage breast cancer following surgical removal to undergo partial breast radiotherapy with proton beam and determine the recurrence rates and side-effects of treatment.

Eligibility criteria:
inclusion criteria: * breast carcinoma * dcis * age 40 years or higher * primary tumor 3 cm or less * lumpectomy with clip placement * axillary node sampling * negative margins exclusion criteria: * distant metastasis * multicentric disease * prior radiation or chemotherapy * active collagen vascular disease * pregnant or lactating * brca mutation * lymph nodes with more than microscopic tumor involvement

Keywords: breast cancer partial breast proton beam
re-covery dvt/pe: global study on treatment secondary prevention of acute venous thromboembolism

Conditions: Venous Thromboembolism

Summary: re-covery is a large, multi-national, multi-center observational study based on new data collection. the study will enroll and characterize patients within 30 days of being diagnosed with an acute dvt and/or pe. the study has two main objectives. objective 1 will characterize the dvt / pe patient population. all patients with a dvt and/or pe will be enrolled for cross-sectional characterization of the vte patient population. objective 2 will compare the safety and effectiveness of dabigatran etexilate regimens for treatment of vte in comparison to vka regimens. patients treated with dabigatran etexilate or vka will be followed up for the occurrence of outcome events for up to one year.


Eligibility criteria:
inclusion criteria: 1. written informed consent provided by the patient in accordance with local regulations 2. diagnosis of an acute dvt and/or pe (for objective 1, assessment of patient for study participation should be done ideally within 14 days but not more than 6 months after diagnosis of the acute vte. for objective 2, patient assessment should occur ideally within 14 days but not more than 30 days from diagnosis) 3. age \>= 18 years 4. for objective 2, the planned anticoagulation therapy should be for at least 3 months 5. for objective 2, dabigatran and vitamin k antagonist patients should be available for follow-up data collection exclusion criteria: 1. need for anticoagulation therapy for conditions other than venous thromboembolism (vte) 2. current participation in a clinical trial for vte indication or current use of an unapproved drug